FDG-PET/CT in Lymphoma: Where Do We Go Now?

被引：24

作者：

Al Tabaa, Yassine ^{[1
]}

Bailly, Clement ^{[2
,3
]}

Kanoun, Salim ^{[4
,5
]}

机构：

[1] Scintidoc Nucl Med Ctr, 25 Rue Clementville, F-34070 Montpellier, France

[2] Univ Nantes, Univ Angers, CNRS, CRCINA,INSERM, F-44093 Nantes, France

[3] Univ Hosp, Nucl Med Dept, F-44093 Nantes, France

[4] Inst Claudius Regaud, Nucl Med Dept, F-31100 Toulouse, France

[5] INSERM UMR 1037, Team 9, Canc Res Ctr Toulouse CRCT, F-31400 Toulouse, France

来源：

CANCERS | 2021年 / 13卷 / 20期

关键词：

FDG-PET; lymphomas; Deauville; 5PS; POSITRON-EMISSION-TOMOGRAPHY; METABOLIC TUMOR VOLUME; STAGE HODGKIN LYMPHOMA; B-CELL LYMPHOMA; INTERNATIONAL HARMONIZATION PROJECT; EARLY CHEMOTHERAPY INTENSIFICATION; PROGRESSION-FREE SURVIVAL; INTERIM F-18-FDG PET; PROGNOSTIC VALUE; RESPONSE ASSESSMENT;

D O I：

10.3390/cancers13205222

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We focus on the role and current applications of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the management of lymphoma patients through improved staging or treatment response assessment or through early PET-driven therapeutic strategies, leading the way to a novel area of personalized medicine, optimizing disease control and toxicity. We discuss the potential future directions of innovative metabolic metrics that are being developed, notably to assess response to new immunotherapy regimens and to provide an improved prognostic factor for predicting patients' survival. Finally, we present new radiopharmaceuticals developed following the identification of pathways or specific receptors in lymphomas, providing great opportunities for molecular imaging in treatment evaluation and management. 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.

引用

页数：19

共 123 条

[91] Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring [J].

Minamimoto, Ryogo ;

Fayad, Luis ;

Advani, Ranjana ;

Vose, Julie ;

Macapinlac, Homer ;

Meza, Jane ;

Hankins, Jordan ;

Mottaghy, Felix ;

Juweid, Malik ;

Quon, Andrew .

RADIOLOGY, 2016, 280 (01) :220-229

[92] Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma [J].

Moskowitz, Alison J. ;

Schoder, Heiko ;

Gavane, Somali ;

Thoren, Katie L. ;

Fleisher, Martin ;

Yahalom, Joachim ;

McCall, Susan J. ;

Cadzin, Briana R. ;

Fox, Stephanie Y. ;

Gerecitano, John ;

Grewal, Ravinder ;

Hamlin, Paul A. ;

Horwitz, Steven M. ;

Kumar, Anita ;

Matasar, Matthew ;

Ni, Andy ;

Noy, Ariela ;

Palomba, M. Lia ;

Perales, Miguel-Angel ;

Portlock, Carol S. ;

Sauter, Craig ;

Straus, David ;

Younes, Anas ;

Zelenetz, Andrew D. ;

Moskowitz, Craig H. .

BLOOD, 2017, 130 (20) :2196-2203

[93] Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab [J].

Muylle, Kristoff ;

Flamen, Patrick ;

Vugts, Danielle J. ;

Guiot, Thomas ;

Ghanem, Ghanem ;

Meuleman, Nathalie ;

Bourgeois, Pierre ;

Vanderlinden, Bruno ;

van Dongen, Guus A. M. S. ;

Everaert, Hendrik ;

Vaes, Melanie ;

Bron, Dominique .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) :1304-1314

[94] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma [J].

Neelapu, S. S. ;

Locke, F. L. ;

Bartlett, N. L. ;

Lekakis, L. J. ;

Miklos, D. B. ;

Jacobson, C. A. ;

Braunschweig, I. ;

Oluwole, O. O. ;

Siddiqi, T. ;

Lin, Y. ;

Timmerman, J. M. ;

Stiff, P. J. ;

Friedberg, J. W. ;

Flinn, I. W. ;

Goy, A. ;

Hill, B. T. ;

Smith, M. R. ;

Deol, A. ;

Farooq, U. ;

McSweeney, P. ;

Munoz, J. ;

Avivi, I. ;

Castro, J. E. ;

Westin, J. R. ;

Chavez, J. C. ;

Ghobadi, A. ;

Komanduri, K. V. ;

Levy, R. ;

Jacobsen, E. D. ;

Witzig, T. E. ;

Reagan, P. ;

Bot, A. ;

Rossi, J. ;

Navale, L. ;

Jiang, Y. ;

Aycock, J. ;

Elias, M. ;

Chang, D. ;

Wiezorek, J. ;

Go, W. Y. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26) :2531-2544

[95] Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG [J].

Pan, Qingqing ;

Luo, Yaping ;

Zhang, Yan ;

Chang, Long ;

Li, Ji ;

Cao, Xinxin ;

Li, Jian ;

Li, Fang .

EJNMMI RESEARCH, 2020, 10 (01)

[96] Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP [J].

Pregno, Patrizia ;

Chiappella, Annalisa ;

Bello, Marilena ;

Botto, Barbara ;

Ferrero, Simone ;

Franceschetti, Silvia ;

Giunta, Francesca ;

Ladetto, Marco ;

Limerutti, Giorgio ;

Menga, Massimo ;

Nicolosi, Maura ;

Priolo, Giorgio ;

Puccini, Benedetta ;

Rigacci, Luigi ;

Salvi, Flavia ;

Vaggelli, Luca ;

Passera, Roberto ;

Bisi, Gianni ;

Vitolo, Umberto .

BLOOD, 2012, 119 (09) :2066-2073

[97] Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma [J].

Radford, John ;

Illidge, Tim ;

Counsell, Nicholas ;

Hancock, Barry ;

Pettengell, Ruth ;

Johnson, Peter ;

Wimperis, Jennie ;

Culligan, Dominic ;

Popova, Bilyana ;

Smith, Paul ;

McMillan, Andrew ;

Brownell, Alison ;

Kruger, Anton ;

Lister, Andrew ;

Hoskin, Peter ;

O'Doherty, Michael ;

Barrington, Sally .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17) :1598-1607

[98] Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial [J].

Raemaekers, John M. M. ;

Andre, Marc P. E. ;

Federico, Massimo ;

Girinsky, Theodore ;

Oumedaly, Reman ;

Brusamolino, Ercole ;

Brice, Pauline ;

Ferme, Christophe ;

van der Maazen, Richard ;

Gotti, Manuel ;

Bouabdallah, Reda ;

Sebban, Catherine J. ;

Lievens, Yolande ;

Re, Allessandro ;

Stamatoullas, Aspasia ;

Morschhauser, Frank ;

Lugtenburg, Pieternella J. ;

Abruzzese, Elisabetta ;

Olivier, Pierre ;

Casasnovas, Rene-Olivier ;

van Imhoff, Gustaaf ;

Raveloarivahy, Tiana ;

Bellei, Monica ;

van der Borght, Thierry ;

Bardet, Stephane ;

Versari, Annibale ;

Hutchings, Martin ;

Meignan, Michel ;

Fortpied, Catherine .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1188-+

[99] Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome [J].

Richter, Julia ;

Huettmann, Andreas ;

Rekowski, Jan ;

Schmitz, Christine ;

Gartner, Selina ;

Rosenwald, Andreas ;

Hansmann, Martin-Leo ;

Hartmann, Sylvia ;

Moeller, Peter ;

Wacker, Hans-Heinrich ;

Feller, Alfred ;

Thorns, Christoph ;

Mueller, Stefan ;

Duehrsen, Ulrich ;

Klapper, Wolfram .

BLOOD CANCER JOURNAL, 2019, 9 (9)

[100] Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study [J].

Roschewski, Mark ;

Dunleavy, Kieron ;

Pittaluga, Stefania ;

Moorhead, Martin ;

Pepin, Francois ;

Kong, Katherine ;

Shovlin, Margaret ;

Jaffe, Elaine S. ;

Staudt, Louis M. ;

Lai, Catherine ;

Steinberg, Seth M. ;

Chen, Clara C. ;

Zheng, Jianbiao ;

Willis, Thomas D. ;

Faham, Malek ;

Wilson, Wyndham H. .

LANCET ONCOLOGY, 2015, 16 (05) :541-549

← 4 5 6 7 8 9 10 11 12 13 →